Effect of calcitonin on vertebral and other fracturesKANIS, J. A; MCCLOSKEY, E. V.QJM (Oxford. 1994. Print). 1999, Vol 92, Num 3, pp 143-149, issn 1460-2725Article

Risk factors in osteoporosis : Menopause, HRT ane osteoporosisKANIS, J. A; MCCLOSKEY, E. V.Maturitas (Amsterdam). 1998, Vol 30, Num 3, pp 229-233, issn 0378-5122Article

Bone turnover and biochemical markers in malignancyKANIS, J. A; MCCLOSKEY, E. V.Cancer. 1997, Vol 80, Num 8, pp 1538-1545, issn 0008-543X, SUPConference Paper

Guidance for the adjustment of FRAX according to the dose of glucocorticoidsKANIS, J. A; JOHANSSON, H; ODEN, A et al.Osteoporosis international. 2011, Vol 22, Num 3, pp 809-816, issn 0937-941X, 8 p.Article

Tumour induced hypercalcaemia: a case for active treatmentO'ROURKE, N. P; MCCLOSKEY, E. V; KANIS, J. A et al.Clinical oncology (Springer. Print). 1994, Vol 6, Num 3, pp 172-176, issn 0936-6555Article

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX^®KANIS, J. A; JOHANSSON, H; ODEN, A et al.Osteoporosis international. 2011, Vol 22, Num 8, pp 2347-2355, issn 0937-941X, 9 p.Article

Bisphosphonates in multiple myelomaKANIS, J. A; MCCLOSKEY, E. V.Cancer. 2000, Vol 88, Num 12, pp 3022-3032, issn 0008-543X, SUPConference Paper

Epidemiology of vertebral osteoporosisKANIS, J. A; MCCLOSKEY, E. V.Bone (New York, NY). 1992, Vol 13, pp S1-S10, issn 8756-3282, SUP2Conference Paper

ClodronateKANIS, J. A; MCCLOSKEY, E. V.Cancer. 1997, Vol 80, Num 8, pp 1691-1695, issn 0008-543X, SUPConference Paper

Use of diphosphonates in hypercalcaemia due to malignancyKANIS, J. A; MCCLOSKEY, E. V; PATERSON, A. H. G et al.Lancet (British edition). 1990, Vol 335, Num 8682, pp 170-171, issn 0140-6736, 2 p.Article

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013COMPSTON, J; BOWRING, C; SELBY, P et al.Maturitas (Amsterdam). 2013, Vol 75, Num 4, pp 392-396, issn 0378-5122, 5 p.Article

Is a calculated total hip BMD of clinical use?SELBY, P. L; MCCLOSKEY, E. V; ROBINSON, J et al.Osteoporosis international. 2000, Vol 11, Num 4, pp 368-371, issn 0937-941XArticle

A precise method for the assessment of tibial ultrasound velocityORGEE, J. M; FOSTER, H; MCCLOSKEY, E. V et al.Osteoporosis international. 1996, Vol 6, Num 1, pp 1-7, issn 0937-941XArticle

Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget's diseaseKHAN, S; MCCLOSKEY, E. V; EYRES, K. S et al.Seminars in arthritis and rheumatism. 1994, Vol 23, Num 4, issn 0049-0172, p. 271Conference Paper

Clodronate in hypercalcaemia and osteolytic bone disease due to breast cancerKANIS, J. A; MCCLOSKEY, E. V; O'ROURKE, N et al.Saudi medical journal. 1993, Vol 14, Num 2, pp 93-97, issn 0379-5284Article

Treatment of skeletal disease in breast cancer with clodronatePATERSON, A. H. G; ERNST, D. S; POWLES, T. J et al.Bone (New York, NY). 1991, Vol 12, pp S25-S30, issn 8756-3282, SUP1Conference Paper

Phosphate binding efficiency of a polyuronic acid in normal subjectsHAMDY, N. A. T; MCCLOSKEY, E. V; NAYLOR, V. A et al.Nephrology, dialysis, transplantation (Print). 1989, Vol 4, Num 9, pp 829-830, issn 0931-0509Article

A FRAX® model for the assessment of fracture probability in BelgiumJOHANSSON, H; KANIS, J. A; MCCLOSKEY, E. V et al.Osteoporosis international. 2011, Vol 22, Num 2, pp 453-461, issn 0937-941X, 9 p.Article

Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social securityJOHANSSON, H; CLARK, P; CARLOS, F et al.Osteoporosis international. 2011, Vol 22, Num 8, pp 2359-2364, issn 0937-941X, 6 p.Article

The effects of a FRAX^® revision for the USAKANIS, J. A; JOHANSSON, H; ODEN, A et al.Osteoporosis international. 2010, Vol 21, Num 1, pp 35-40, issn 0937-941X, 6 p.Article

A meta-analysis of previous fracture and subsequent fracture risk : Fractures in osteoporosisKANIS, J. A; JOHNELL, O; MCCLOSKEY, E. V et al.Bone (New York, NY). 2004, Vol 35, Num 2, pp 375-382, issn 8756-3282, 8 p.Article

Alendronate in the treatment of Paget's disease of boneKHAN, S. A; VASIKARAN, S; MCCLOSKEY, E. V et al.Bone (New York, NY). 1997, Vol 20, Num 3, pp 263-271, issn 8756-3282Article

Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to boneTAUBE, T; BENETON, M. N. C; WILLIAMS, J. L et al.British journal of urology (Print). 1993, Vol 72, Num 1, pp 98-103, issn 0007-1331Article

Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancyBICKERSTAFF, D. R; O'DOHERTY, D. P; MCCLOSKEY, E. V et al.Bone (New York, NY). 1991, Vol 12, Num 1, pp 17-20, issn 8756-3282Article

Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonateO'DOHERTY, D. P; BICKERSTAFF, D. R; MCCLOSKEY, E. V et al.Journal of bone and mineral research (Print). 1990, Vol 5, Num 5, pp 483-491, issn 0884-0431Article